Calcineurin inhibitors and NFAT-regulated gene expression

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1379-1386

  Sommerer, Claudia ^a   Meuer, Stefan ^b   Zeier, Martin ^a   Giese, Thomas ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Ciclosporin A; Gene expression; Immune monitoring; Monitoring; NFAT; Tacrolimus

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; FINGOLIMOD; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MYCOPHENOLIC ACID; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ASSAY; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; ENZYME ACTIVITY; GAMMA INTERFERON GENE; GENE; GENE EXPRESSION REGULATION; GRAFT RECIPIENT; GRAFT REJECTION; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR GENE; HUMAN; IL 2 GENE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT MONITORING; PHARMACODYNAMIC MONITORING; PHARMACODYNAMIC MONITORING ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR ALPHA GENE; UNSPECIFIED SIDE EFFECT; UPREGULATION;

CALCINEURIN; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NFATC TRANSCRIPTION FACTORS; ORGAN TRANSPLANTATION;

EID: 84862759750     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.09.041     Document Type: Review

References (62)

1. Meier-Kriesche H.U., Li S., Gruessner R.W., et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006, 6:1111-1131.
2. Hariharan S., Johnson C.P., Bresnahan B.A., Taranto S.E., McIntosh M.J., Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342:605-612.
3. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378-383.
4. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009, 69:2227-2243.
5. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Chapman J.R., Allen R.D. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557-565.
6. Morath C., Mueller M., Goldschmidt H., Schwenger V., Opelz G., Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 2004, 15:1582-1588.
7. Birkeland S.A., Løkkegaard H., Storm H.H. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000, 355:1886-1887.
8. Mahalati K., Belitsky P., West K., et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001, 12:828-833.
9. Morris R.G., Russ G.R., Cervelli M.J., Juneja R., McDonald S.P., Mathew T.H. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002, 24:479-486.
10. Levy G., Thervet E., Lake J., Uchida K. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002, 73(9 Suppl.):S12-S18. on behalf of the CONCERT group.
11. International Neoral Study Group Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002, 2:148-156.
12. Knight S.R., Morris P.J. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007, 83:1525-1535.
13. Wallemacq P., Armstrong V.W., Brunet M., et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009, 31:139-152.
14. Stefoni S., Midtved K., Cole E., et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005, 79:577-583.
15. Citterio F., Scata M.C., Romagnoli J., Nanni G., Castagneto M. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion. Transplantation 2005, 79:802-806.
16. Fukudo M., Yano I., Katsura T., et al. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection. Drug Metab Pharmacokinet 2010, 25:411-417.
17. Halloran P.F., Helms L.M., Kung L., Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999, 68:1356-1361.
18. Stein C.M., Murray J.J., Wood A.J. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of the cyclosporine effect. Clin Chem 1999, 45:1477-1484.
19. Hartel C., Fricke L., Schumacher N., Kirchner H., Müller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte co-stimulation: a quantitative measure of the efficacy of cyclosporine A-based immunosuppression. Clin Chem 2002, 48:2225-2231.
20. Hartel C., Schumacher N., Fricke L., Ebel B., Kirchner H., Müller-Steinhardt M. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin Chem 2004, 50:141-151.
21. Fruman D.A., Klee C.B., Bierer B.E., Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 1992, 89:3686-3690.
22. O'Keefe S.J., Tamura J., Kincaid R.L., Tocci M.J., O'Neill E.A. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992, 357:692-694.
23. Clipstone N.A., Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357:695-697.
24. Kel A., Kel-Margoulis O., Babenko V., Wingender E. Recognition of NFATp/AP-1 composite elements within genes induced upon the activation of immune cells. J Mol Biol 1999, 288:353-376.
25. Sellar K.J., van Rossum H.H., Romijn F.P., Smit N.P., de Fijter J.W., van Pelt J. Spectrophotometric assay for calcineurin activity in leukocytes isolated from human blood. Anal Biochem 2006, 358:104-110.
26. van Rossum H.H., Romijn F.P., Sellar K.J., et al. Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies. Clin Chem 2008, 54:517-524.
27. Millan O., Brunet M., Campistol J.M., et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 2003, 49:1891-1899.
28. Brunet M., Campistol J.M., Millán O., et al. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). Int Immunopharmacol 2003, 3:987-999.
29. Barten M.J., Dhein S., Chang H., et al. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood. J Immunol Methods 2003, 283:99-114.
30. Barten M.J., Tarnok A., Garbade J., et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007, 40:50-63.
31. Giese T., Zeier M., Schemmer P., et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004, 77:339-344.
32. Derveaux S., Vandesompele J., Hellemans J. How to do successful gene expression analysis using real-time PCR. Methods 2010, 50:227-230.
33. Giese T., Zeier M., Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004, 19(suppl. 4):iv55-iv60.
34. Wieland E., Olbricht C.J., Süsal C., et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010, 32:560-572.
35. Matloubian M., Lo C.G., Cinamon G., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
36. Sommerer C., Morath C., Giese T., Meuer S., Zeier M. Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients. Transplant Proc 2008, 40:1416-1418.
37. Sommerer C., Giese T., Schmidt J., Meuer S., Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 2008, 85:15-21.
38. Billing H., Giese T., Sommerer C., et al. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplant 2010, 14:844-851.
39. Sommerer C., Konstandin M., Dengler T., et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006, 82:1280-1285.
40. Sommerer C., Zeier M., Meuer S., Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010, 89:1417-1423.
41. Konstandin M.H., Sommerer C., Doesch A., et al. Pharmacodynamic cyclosporine A monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007, 20:1036-1043.
42. Sommerer C., Hartschuh W., Enk A., Meuer S., Zeier M., Giese T. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008, 22:549-554.
43. Sommerer C., Giese T., Meuer S., Zeier M. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit?. Nephrol Dial Transplant 2009, 24:21-27.
44. Giese T., Sommerer C., Zeier M., Meuer S. Approaches towards individualized immune intervention. Dig Dis 2010, 28:45-50.
45. Sommerer C., Zeier M., Meuer S., Giese T. Immunomonitoring of NFAT-regulated gene expression: clinical benefit of clinical stable renal allograft recipients. Ther Drug Monit 2011, 33:469. [Abstract #P198].
46. Sommerer C., Beimler J., Meuer S., Giese T., Zeier M. Monitoring of NFAT-regulated gene expression for safe tapering of CNI immunosuppression in BK virus positive renal transplant patients. J Am Soc Nephrol 2007, 18:1000. [Abstract #4003].
47. Sommerer C., Dannewitz B., Kruck E.M., Giese T., Meuer S., Zeier M. Residual NFAT-regulated gene expression as prognostic indicator for ciclosporin A induced gingival overgrowth. Am J Transplant 2010, 10(Suppl. 4):529. [Abstract #1720].
48. Sommerer C., Zeier M., Meuer S., Giese T. Pharmacodynamic monitoring of CsA therapy in the early posttransplant period. Kidney Int 2011, (Suppl.):1000. [Abstract #MO518].
49. Sommerer C., Zeier M., Czock D., Schnitzler P., Meuer S., Giese T. Pharmacodynamic disparities in tacrolimus treated patients developing CMV viremia. Ther Drug Monit 2011, 33:373-379.
50. Kung L., Halloran P.F. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 2000, 70:327-335.
51. van Rossum H.H., de Fijter J.W., van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit 2010, 32:3-10.
52. Fukudo M., Yano I., Masuda S., Okuda M., Inui K. Distinct inhibitory effects of tacrolimus and cyclosporin A on calcineurin phosphatase activity. J Pharmacol Exp Ther 2005, 312:816-825.
53. Zahn A., Schott N., Hinz U., et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transpl 2011, 17:466-473.
54. Herden U., Kromminga A., Hagel C., et al. Monitoring of nuclear factor of activated T-cell regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine A. Ther Drug Monit 2011, 33:185-191.
55. Billing H., Sommerer C., Giese T., Meuer S., Tönshoff B., Czock D. Differential suppression of NFAT-regulated genes on ciclosporin A therapy in paediatric and adult renal allograft recipients. Klin Padiatr 2011, 223:S38. [Abstract #P010].
56. Pratschke J., Merk V., Reutzel-Selke A., et al. Potent early immune response after kidney transplantation in patients of the European senior transplant program. Transplantation 2009, 87:992-1000.
57. Gill J., Bunnapradist S., Danovitch G.M., Gjertson D., Gill J.S., Cecka M. Outcomes of kidney transplantation from older living donors to older recipients. Am J Kidney Dis 2008, 52:541-552.
58. Comeau S., Jensen L., Cockfield S.M., Sapijaszko M., Gourishankar S. Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience. Transplantation 2008, 86:535-541.
59. Kasiske B.L., Snyder J.J., Gilbertson D.T.G., Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004, 4:905-913.
60. Sommerer C, Schnitzler P, Meuer S, Zeier M, Giese T. Pharmacodynamic monitoring of ciclosporin A in renal transplant recipients >65years reveals risk of opportunistic infection. Ther Drug Monit in press.
61. Boleslawski E., Conti F., Sanquer S., et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004, 77:1815-1820.
62. Millán O., Benitez C., Guillén D., et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol 2010, 137:337-346.